首页> 美国卫生研究院文献>World Journal of Transplantation >Biomarkers in renal transplantation: An updated review
【2h】

Biomarkers in renal transplantation: An updated review

机译:肾移植中的生物标志物:最新评论

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genomics, proteomics and molecular biology lead to tremendous advances in all fields of medical sciences. Among these the finding of biomarkers as non invasive indicators of biologic processes represents a useful tool in the field of transplantation. In addition to define the principal characteristics of the biomarkers, this review will examine the biomarker usefulness in the different clinical phases following renal transplantation. Biomarkers of ischemia-reperfusion injury and of delayed graft function are extremely important for an early diagnosis of these complications and for optimizing the treatment. Biomarkers predicting or diagnosing acute rejection either cell-mediated or antibody-mediated allow a risk stratification of the recipient, a prompt diagnosis in an early phase when the histology is still unremarkable. The kidney solid organ response test detects renal transplant recipients at high risk for acute rejection with a very high sensitivity and is also able to make diagnosis of subclinical acute rejection. Other biomarkers are able to detect chronic allograft dysfunction in an early phase and to differentiate the true chronic rejection from other forms of chronic allograft nephropathies no immune related. Finally biomarkers recently discovered identify patients tolerant or almost tolerant. This fact allows to safely reduce or withdrawn the immunosuppressive therapy.
机译:基因组学,蛋白质组学和分子生物学在医学科学的各个领域都取得了巨大的进步。其中,作为生物过程非侵入性指标的生物标志物的发现代表了移植领域的有用工具。除了定义生物标志物的主要特征外,本综述还将检查肾移植后不同临床阶段中生物标志物的有用性。缺血再灌注损伤和移植物功能延迟的生物标志物对于这些并发症的早期诊断和优化治疗极为重要。预测或诊断细胞介导或抗体介导的急性排斥反应的生物标记物可对受体进行风险分层,这在组织学仍不明显的早期即刻诊断。肾脏实体器官反应测试可以非常高的灵敏度检测出具有高急性排斥反应风险的肾移植受者,并且还可以进行亚临床急性排斥反应的诊断。其他生物标记物能够在早期阶段检测出慢性同种异体移植功能障碍,并将真正的慢性排斥反应与其他形式的与免疫无关的慢性同种异体移植肾病区别开来。最终,最近发现的生物标记物鉴定出可以耐受或几乎耐受的患者。这一事实使得可以安全地减少或撤消免疫抑制疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号